Youthfulness of marrow Adipoqcells maintained by Cbfβ facilitates stem cell-based bone repair.
Key claim: Cbfβ in bone-marrow Adipoq+ cells preserves chromatin accessibility at DNA-repair loci to prevent BMAC senescence and SASP, thereby maintaining skeletal stem/progenitor cells and fracture repair, and its age-related decline can be rescued by senolytics or Cbfβ overexpression in mice.
Abstract
Exhaustion of skeletal stem and progenitor cells (SSPCs) drives age-related delays in fracture repair, yet the upstream regulators of SSPC maintenance are unclear. We identify that core-binding factor β (Cbfβ) in bone marrow Adipoqcells (BMACs) is essential for maintaining SSPC number and function. Cbfβ deletion in BMACs (CKO) leads to SSPC depletion, including periosteal populations, and impairs bicortical fracture healing in mice. Multi-omics (RNA-seq, CUT&Tag-seq, and ATAC-seq) reveal that Cbfβ preserves chromatin accessibility at DNA repair loci, maintaining genomic stability, preventing BMAC senescence, and mitigating the senescence-associated secretory phenotype (SASP). Senolytic therapy alleviates BMAC senescence, restores SSPC populations, and improves bone repair in CKO mice. In both humans and mice, Cbfβ expression declines with aging, accompanied by increased BMAC senescence. AAV-mediated Cbfβ overexpression restores aging-related bone repair and SSPC decline. These findings reveal a novel mechanism in which Cbfβ in BMACs regulates SSPC maintenance via a senescence/SASP axis, offering a potential therapeutic strategy for age-related bone repair deficits.
Why this matters
Bone-marrow adipocyte-lineage cells are increasingly framed as an active senescent niche compartment rather than inert filler, and this study nominates Cbfβ-maintained chromatin accessibility at DNA-repair loci as a specific upstream lever controlling whether they turn SASP-positive and starve the skeletal stem/progenitor pool. The rescue by both a canonical senolytic and by AAV-Cbfβ ties a transcription-factor/chromatin mechanism to the same regenerative endpoint (fracture repair), sharpening where senolytics might act in aged bone. Evidence remains mouse-only, with no human Cbfβ perturbation or bone-healing outcome data.